Clareo Health | Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Either treatment-naïve patients, or those who have discontinued their Rheumatoid Arthritis-directed medication due to intolerability or insufficient efficacy
At least 9 out of 68 tender joints; 6 out of 66 swollen joints; morning stiffness 45 min
C-Reactive Protein \>=1.8 mg/dl confirmed during screening period
Non-poor Cytochrome P2D6 metabolizer status
You may not be if
Functional Rheumatoid Arthritis class IV
Fever
Infections with hepatitis B, or C, or HIV
Presence or history (\<5 years) of cancer
Manifest or latent tuberculosis
Functional abnormalities (including laboratory values) judged as clinically relevant
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
